J&J, states settle on Risperdal

Share this article:

As part of a $181-million settlement with states to resolve charges of improper marketing and advertising, Johnson & Johnson agreed to stop several practices regarding Ripserdal and its cousin Invega.

These include misusing CME programs for marketing; awarding grants to doctors based on prescribing habits; presenting information that is not scientifically sound; and disseminating reprints with off-label usage information.

At press time, J&J was expected to pay up to $2.2 billion for the same allegations by DOJ involving these and other drugs.

On its website, J&J said it's not admititng any Risperdal wrongdoing.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?